Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Status:
Completed
Trial end date:
2014-01-16
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as epirubicin and docetaxel use different ways to
stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such
as pegfilgrastim may increase the number of immune cells found in bone marrow or peripheral
blood and may help a person's immune system recover from the side effects of chemotherapy.
PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin and docetaxel
with pegfilgrastim in treating women who have locally advanced or inflammatory breast cancer.